出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年12月
製品 (ブドウ糖、HIV、C 型肝炎、妊娠)、プラットフォーム (マイクロフルイディクス、ディップスティック、免疫測定)、購入 (OTC、処方箋)、サンプル (血液、尿)、ユーザー (薬局、病院、在宅医療) – 2027 年までの世界予測
Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) – Global Forecast to 2027
| ページ数 | 383 |
| 図表数 | 382 |
| 種別 | 英文調査報告書 |
| 価格 |
The global point-of-care and rapid diagnostics market is projected to reach USD 75.5 Billion by 2027 from USD 45.4 Billion in 2022, at a CAGR of 10.7% during the forecast period. The growth in the point-of-care and rapid diagnostics market is majorly driven by the significant rising cases of infectious diseases, diabetes, cardiovascular diseases and cancer. Also, rapidly growing older population, and increasing research & funding initiatives by government to support the development and adoption of POC is anticipated to promote the growth of market. The rising number of CLIA waivers over the years indicates a favorable approval environment, which will encourage players to focus on the development of point-of-care diagnostic products
However, are a lack of alignment with test results obtained from laboratories and stringent and time-consuming approval policies are expected to restrain market growth in the coming years.
“The glucose monitoring device held the significant share of point-of-care and rapid diagnostics market during the forecast period.
Based on products, the point-of-care and rapid diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, thyroid stimulating hormone testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products.
The glucose monitoring device held the significant share of point-of-care and rapid diagnostics market during the forecast period. The rising diabeteic patient population worldwide and growing awarness about the presnece of self glucose monitorng and ongoing technological advanacemnts are anticiapted to paly a critical role in propelling the growth of the segment.
“The Lateral Flow Assays segment accounted for the largest share of the point-of-care diagnostics market, by platform, in 2021”
Based on platform, the point-of-care and rapid diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The growing adoption of lateral flow assays in point-of care testing facilities owing to the greater advantages offered by lateral low assay by replacing conventional, lengthy laboratory procedures are likely to contribute towards to the growth of this segment during the forecast period.
“The OTC Testing Products segment, by mode of purchase segment, accounted for the largest share of the global point-of-care and rapid diagnostics market in 2021”
On the basis of mode of purchase, the point-of-care and rapid diagnostics market is segmented into OTC testing products and prescription-based testing products. The OTC testing products segment accounted for the largest share of the market in 2021. Factors such as the rising prevalence of diabetes in developing countries where glucose monitors are available without a prescription, growing online purchase of OTC point-of-care products, increasing patient preference for OTC products for the diagnosis of pregnancy, lower cost of OTC products, and the increasing preference for self-monitoring are driving the growth of the OTC testing products market
“On the basis of sample, blood segment is accounted for the largest share of the global point-of-care and rapid diagnostics market in 2021”
On the basis of sample, the point-of-care and rapid diagnostics market is segment into blood, urine, nasal and oropharyngeal swabs, and other samples. The blood sample segment accounted for the largest market share 2021. Factors such as the rising prevalence of HIV, diabetes, and malaria and the growing applications of blood samples for the diagnosis of various diseases are anticipated to boost the growth of this segment.
“On the basis of End Users, clinical laboratories segment accounted for the largest share of point-of-care and rapid diagnostics market in 2021”
On the basis of end users, the point-of-care and rapid diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians’ offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users.
The clinical laboratories segment accounted for the largest share of point-of-care and rapid diagnostics market in 2021. The recent outbreak of COVID-19 positively impacted the clinical laboratories segment, as the pandemic has boosted clinical laboratory testing services. Based on the study published by the National Center for Biotechnology Information in July 2020, the use of clinical diagnostics, including molecular and serological testing approaches for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) testing, has increased. The increasing number of COVID-19 variants is further likely to drive the growth of the clinical laboratories segment. In February 2021, Thermo Fisher Scientific launched the Towpaths COVID–19 HT Kit for use on its automated amplitude platform to increase its COVID-19 testing capacity by combining Thermo Fisher’s extraction and real-time PCR instruments with liquid handling products from Tecan Group.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global point-of-care and rapid diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases in the region, growing number of rapid point-of-care products approvals, presence of well-established players, and government initiatives to support the wider adoption of rapid testing are some of the key factors driving the growth of the North American point-of-care and rapid diagnostics market.
On the other hand, the Asia Pacific market is projected to register the highest growth during the forecast period. This is attributed to the presence of densely populated countries in the region such as China and India; with increasing prevalence of target diseases, growing awareness of POCT products, emergence of new rapid diagnostic kits manufacturer, expansion of healthcare infrastructure, growing initiatives by government to promote the adoption of POCT, and increased focus of key players in establishing their foothold in Asian Countries.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%
The major players operating in the point-of-care and rapid diagnostics market are Abbott (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and F. Hoffman-La Roche Ltd. (Switzerland), Quidel Corporation (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux SA (France).
Research Coverage
This report studies the point-of-care and rapid diagnostics market based on product, platform, mode of purchase, sample, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point-of-care diagnostics market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point-of-care diagnostics market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point-of-care diagnostics market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目次
1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED 49
1.3.2 GEOGRAPHIC SCOPE 49
1.3.3 INCLUSIONS AND EXCLUSIONS 50
1.3.4 YEARS CONSIDERED 50
1.4 CURRENCY 51
1.5 STAKEHOLDERS 51
1.6 SUMMARY OF CHANGES 51
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 1 RESEARCH DESIGN 53
2.1.1 SECONDARY RESEARCH 54
2.1.2 PRIMARY RESEARCH 55
2.1.2.1 Key data from primary sources 55
2.1.2.2 Key industry insights 56
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 56
FIGURE 3 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARIES 57
2.2 MARKET SIZE ESTIMATION 57
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 58
2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION 58
2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION 59
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET 60
2.2.3 PRIMARY RESEARCH VALIDATION 60
2.3 DATA TRIANGULATION 61
FIGURE 6 DATA TRIANGULATION METHODOLOGY 61
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 62
2.4.1 RESEARCH ASSUMPTIONS 62
2.4.2 RESEARCH LIMITATIONS 62
3 EXECUTIVE SUMMARY 63
FIGURE 7 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 63
FIGURE 8 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2022 VS. 2027 (USD MILLION) 64
FIGURE 9 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022 VS. 2027 (USD MILLION) 65
FIGURE 10 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 65
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET 66
4 PREMIUM INSIGHTS 67
4.1 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET OVERVIEW 67
FIGURE 12 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET 67
4.2 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 68
FIGURE 13 GLUCOSE MONITORING PRODUCTS SEGMENT WILL DOMINATE MARKET IN 2027 68
4.3 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SHARE, BY MODE OF PURCHASE (2022) 69
FIGURE 14 OTC TESTING PRODUCTS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE IN 2022 69
4.4 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SHARE, BY PLATFORM, 2022 VS. 2027 69
FIGURE 15 LATERAL FLOW ASSAYS WILL CONTINUE TO DOMINATE MARKET IN 2027 69
4.5 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 17 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71
5.2.1 DRIVERS 72
5.2.1.1 High prevalence of infectious diseases 72
FIGURE 18 HIV INFECTION, BY REGION, 2021 72
5.2.1.2 Increasing incidence of target conditions 73
5.2.1.3 Supportive government policies 73
5.2.1.4 Dearth of skilled laboratory technicians 74
5.2.1.5 Rising number of CLIA-waived POC tests 74
TABLE 1 RECENT WAIVERS FOR PRODUCTS 74
5.2.2 RESTRAINTS 75
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints 75
5.2.2.2 Stringent regulatory policies 75
5.2.3 OPPORTUNITIES 76
5.2.3.1 Emerging markets 76
5.2.3.2 Healthcare decentralization 76
5.2.3.3 Increasing provider awareness about novel technologies 77
5.2.3.4 POC tests with multiplexing capabilities 77
5.2.3.5 Growing investments and funding for product development 78
5.2.4 CHALLENGES 78
5.2.4.1 Lack of alignment with definitive central lab methods 78
5.2.4.2 Inadequate adoption of POC devices in professional settings 79
5.2.4.3 Reluctance to change existing diagnostic practices 79
5.2.4.4 Premium pricing of novel platforms 79
5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS 80
5.3.1 SEPSIS BIOMARKERS 80
5.3.2 STROKE/CARDIAC MARKERS 81
5.3.3 THYROID TESTING 81
5.3.4 DNA TESTING 81
5.3.5 ENDOCRINE TESTING 82
5.3.6 RESPIRATORY DIAGNOSTICS 82
5.4 REGULATORY LANDSCAPE 82
TABLE 2 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES 82
5.4.1 KEY REGULATORY GUIDELINES 83
5.4.1.1 US 83
FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES 83
5.4.1.2 Canada 84
FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES 84
5.4.1.3 Europe 84
FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 85
5.4.1.4 Japan 86
FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 86
5.4.1.5 China 86
TABLE 3 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87
5.4.1.6 India 87
FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES 87
5.4.1.7 Brazil 87
FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 88
5.5 VALUE CHAIN ANALYSIS 88
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES 88
5.6 SUPPLY CHAIN ANALYSIS 89
5.6.1 PROMINENT COMPANIES 89
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 89
5.6.3 END USERS 90
FIGURE 26 SUPPLY CHAIN ANALYSIS 90
5.7 PRICING TREND ANALYSIS 90
TABLE 4 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD) 90
TABLE 5 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2021 (USD) 91
TABLE 6 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2021 (USD) 91
5.8 PORTER’S FIVE FORCES 92
5.8.1 OVERVIEW 92
TABLE 7 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
5.8.2 BARGAINING POWER OF BUYERS 92
5.8.3 BARGAINING POWER OF SUPPLIERS 92
5.8.4 THREAT OF NEW ENTRANTS 92
5.8.5 THREAT OF SUBSTITUTES 93
5.8.6 INTENSITY OF COMPETITIVE RIVALRY 93
5.9 PATENT ANALYSIS 93
FIGURE 27 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012–NOVEMBER 2022) 93
FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–NOVEMBER 2022) 94
FIGURE 29 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 94
5.10 KEY CONFERENCES AND EVENTS 95
TABLE 8 POINT-OF-CARE & RAPID DIAGNOSTICS MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS, 2021–2023 95
5.11 CASE STUDY 95
5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 95
TABLE 9 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS 95
FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 96
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 96
5.12.1 KEY STAKEHOLDERS 96
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS 96
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 97
5.13 KEY BUYING CRITERIA 97
TABLE 11 KEY BUYING CRITERIA FOR PRODUCTS 97
6 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT 98
6.1 INTRODUCTION 99
TABLE 12 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 99
6.2 GLUCOSE MONITORING PRODUCTS 100
TABLE 13 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 14 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 101
TABLE 15 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 101
TABLE 16 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 102
TABLE 17 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 102
TABLE 18 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 103
6.2.1 STRIPS 103
6.2.1.1 Strips make blood glucose testing easy and hassle-free 103
TABLE 19 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION) 103
6.2.2 METERS 104
6.2.2.1 Extremely helpful in monitoring blood glucose levels and adjusting therapeutic regimens 104
TABLE 20 GLUCOSE MONITORING METERS MARKET, BY REGION, 2020–2027 (USD MILLION) 104
6.2.3 LANCETS AND LANCING DEVICES 104
6.2.3.1 Lancets and lancing devices segment to register lower growth in glucose monitoring products market 104
TABLE 21 GLUCOSE MONITORING LANCETS AND LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 105
6.3 COVID-19 TESTING PRODUCTS 105
6.3.1 COVID-19 PANDEMIC ACCELERATED DEMAND FOR POC/RAPID DIAGNOSTIC PRODUCTS 105
TABLE 22 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 106
TABLE 23 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 106
TABLE 24 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 107
TABLE 25 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 107
TABLE 26 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 108
6.4 CARDIOMETABOLIC MONITORING PRODUCTS 108
TABLE 27 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 28 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 109
TABLE 29 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 109
TABLE 30 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 110
TABLE 31 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 110
TABLE 32 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 111
6.4.1 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 111
6.4.1.1 Technological advancements in blood gas/electrolyte products to drive market 111
TABLE 33 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 112
6.4.2 CARDIAC MARKER TESTING PRODUCTS 112
6.4.2.1 Rising prevalence of heart diseases and development of new POC test to support market growth 112
TABLE 34 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 113
6.4.3 HBA1C TESTING PRODUCTS 113
6.4.3.1 Government initiatives promoting regular use of HbA1c testing 113
TABLE 35 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 114
6.5 INFECTIOUS DISEASE TESTING PRODUCTS 115
TABLE 36 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 37 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 116
TABLE 38 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 116
TABLE 39 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 117
TABLE 40 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 117
TABLE 41 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 118
6.5.1 HIV TESTING PRODUCTS 118
6.5.1.1 Rising prevalence of HIV to drive market 118
TABLE 42 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 118
TABLE 43 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 119
TABLE 44 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 119
TABLE 45 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 120
6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS 120
6.5.2.1 POCT products for diagnosis of respiratory infections offer lower sensitivity 120
TABLE 46 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 121
TABLE 47 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 121
TABLE 48 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 122
TABLE 49 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 122
6.5.3 HEPATITIS C TESTING PRODUCTS 122
6.5.3.1 Central and East Asia among highly affected regions by hepatitis C 122
TABLE 50 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 123
TABLE 51 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 123
TABLE 52 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 124
TABLE 53 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 124
6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 124
6.5.4.1 Rising prevalence of HAIs to drive market 124
TABLE 54 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 125
TABLE 55 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 125
TABLE 56 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 126
TABLE 57 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 126
6.5.5 INFLUENZA TESTING PRODUCTS 127
6.5.5.1 Rising influenza prevalence to drive demand for influenza testing products 127
TABLE 58 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 127
TABLE 59 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 128
TABLE 60 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 128
TABLE 61 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 129
6.5.6 TROPICAL DISEASE TESTING PRODUCTS 129
6.5.6.1 Increasing government funding for use of POC in tropical disease testing to support market growth 129
TABLE 62 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 130
TABLE 63 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 130
TABLE 64 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASES PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 131
TABLE 65 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 131
6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 131
TABLE 66 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 67 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 132
TABLE 68 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 133
TABLE 69 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 133
TABLE 70 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 134
6.5.7.1 Syphilis testing products 134
6.5.7.1.1 Introduction of rapid tests for syphilis to support market growth 134
TABLE 71 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 135
6.5.7.2 Human papillomavirus (HPV) testing products 135
6.5.7.2.1 Technological advancements to aid market growth 135
TABLE 72 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 136
6.5.7.3 Chlamydia trachomatis testing products 136
6.5.7.3.1 Growing incidence of chlamydia and rising awareness among patients to drive market 136
TABLE 73 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 137
6.5.7.4 Herpes simplex virus (HSV) testing products 137
6.5.7.4.1 Increasing incidence of HSV to boost adoption of rapid tests 137
TABLE 74 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 137
6.5.8 TUBERCULOSIS (TB) TESTING PRODUCTS 138
6.5.8.1 Rising prevalence of TB and initiatives by governments to propel demand for rapid TB tests 138
TABLE 75 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 138
TABLE 76 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 139
TABLE 77 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 139
TABLE 78 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 140
6.5.9 CLOSTRIDIUM DIFFICILE INFECTION (CDI) TESTING PRODUCTS 140
6.5.9.1 Increasing cases of CDI infections among hospitalized patients to support market growth 140
TABLE 79 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 140
TABLE 80 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 141
TABLE 81 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 141
TABLE 82 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CDI TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 142
6.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 142
TABLE 83 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 142
TABLE 84 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 143
TABLE 85 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 143
TABLE 86 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 144
6.6 COAGULATION MONITORING PRODUCTS 144
TABLE 87 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 88 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 145
TABLE 89 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 145
TABLE 90 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 146
TABLE 91 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 146
TABLE 92 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 147
6.6.1 PT/INR TESTING PRODUCTS 147
6.6.1.1 Most commonly used coagulation monitoring method 147
TABLE 93 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 148
6.6.2 ACT/APTT TESTING PRODUCTS 148
6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 148
TABLE 94 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 148
6.7 PREGNANCY AND FERTILITY TESTING PRODUCTS 149
TABLE 95 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 96 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 149
TABLE 97 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 150
TABLE 98 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 150
TABLE 99 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 151
TABLE 100 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 151
6.7.1 PREGNANCY TESTING PRODUCTS 152
6.7.1.1 Rising inclination toward home testing to support market growth 152
TABLE 101 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 152
6.7.2 FERTILITY TESTING PRODUCTS 152
6.7.2.1 Increasing awareness of fertility testing to drive market 152
TABLE 102 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 153
6.8 TUMOR/CANCER MARKER TESTING PRODUCTS 153
6.8.1 INCREASING PREVALENCE OF CANCER TO BOOST DEMAND FOR RAPID TESTING 153
TABLE 103 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 154
TABLE 104 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 154
TABLE 105 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 155
TABLE 106 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 155
TABLE 107 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 156
6.9 URINALYSIS TESTING PRODUCTS 156
6.9.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS TO DRIVE MARKET 156
TABLE 108 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 157
TABLE 109 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 157
TABLE 110 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 158
TABLE 111 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 158
TABLE 112 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 159
6.10 CHOLESTEROL TESTING PRODUCTS 159
6.10.1 RISING OBESITY LEVELS TO DRIVE ADOPTION OF CHOLESTEROL TESTING PRODUCTS 159
TABLE 113 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 160
TABLE 114 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 160
TABLE 115 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 161
TABLE 116 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 161
TABLE 117 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 162
6.11 HEMATOLOGY TESTING PRODUCTS 162
6.11.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS TO IMPEDE MARKET GROWTH 162
TABLE 118 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 163
TABLE 119 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 163
TABLE 120 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 164
TABLE 121 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 164
TABLE 122 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 165
6.12 DRUGS-OF-ABUSE TESTING PRODUCTS 165
6.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO BOOST DEMAND FOR TESTING 165
TABLE 123 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 166
TABLE 124 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 166
TABLE 125 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 167
TABLE 126 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 167
TABLE 127 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 168
6.13 FECAL OCCULT TESTING PRODUCTS 168
6.13.1 LACK OF PROPER TRAINING FOR FECAL OCCULT TESTING TO HAMPER MARKET GROWTH 168
TABLE 128 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 169
TABLE 129 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 169
TABLE 130 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 170
TABLE 131 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 170
TABLE 132 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 171
6.14 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS 171
6.14.1 RISING CASES OF THYROID TO BOOST ADOPTION OF RAPID TESTS 171
TABLE 133 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 171
TABLE 134 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 172
TABLE 135 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 172
TABLE 136 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY SAMPLE, 2020–2027 (USD MILLION) 173
TABLE 137 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 173
6.15 OTHER PRODUCTS 173
TABLE 138 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 174
TABLE 139 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 174
TABLE 140 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 175
TABLE 141 OTHER POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 175
TABLE 142 OTHER POINT-OF-CARE AND RAPID DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 176
7 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM 177
7.1 INTRODUCTION 178
TABLE 143 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 178
7.2 LATERAL FLOW ASSAYS 178
7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET 178
TABLE 144 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2020–2027 (USD MILLION) 179
7.3 IMMUNOASSAYS 179
7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH 179
TABLE 145 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 180
7.4 MICROFLUIDICS 180
7.4.1 EMERGING PLATFORM IN POC DIAGNOSTICS MARKET 180
TABLE 146 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION) 181
7.5 DIPSTICKS 181
7.5.1 DIPSTICKS HELP IN ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS 181
TABLE 147 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2020–2027 (USD MILLION) 182
7.6 MOLECULAR DIAGNOSTICS 182
TABLE 148 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2020–2027 (USD MILLION) 183
TABLE 149 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 183
7.6.1 RT-PCR 184
7.6.1.1 COVID-19 testing boosted demand for RT-PCR technology 184
TABLE 150 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2020–2027 (USD MILLION) 184
7.6.2 INAAT 184
7.6.2.1 Cost benefits of INAAT to drive adoption 184
TABLE 151 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2020–2027 (USD MILLION) 185
7.6.3 OTHER TECHNOLOGIES 185
TABLE 152 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 186
8 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE 187
8.1 INTRODUCTION 188
TABLE 153 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 188
8.2 OTC TESTING PRODUCTS 188
8.2.1 RISING FOCUS ON HOME CARE TO BOOST DEMAND FOR OTC TESTING PRODUCTS 188
TABLE 154 OTC POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 189
8.3 PRESCRIPTION-BASED TESTING PRODUCTS 189
8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT TO DRIVE MARKET 189
TABLE 155 PRESCRIPTION-BASED POINT-OF-CARE AND RAPID TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 190
9 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE 191
9.1 INTRODUCTION 192
TABLE 156 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 192
9.2 BLOOD 192
9.2.1 RISING APPLICATION OF BLOOD SAMPLES IN DETECTION OF VARIOUS DISEASES TO DRIVE GROWTH 192
TABLE 157 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION) 193
9.3 URINE 193
9.3.1 GROWING PREVALENCE OF KIDNEY DISORDERS TO BOOST MARKET GROWTH 193
TABLE 158 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2020–2027 (USD MILLION) 194
9.4 NASAL AND OROPHARYNGEAL SWABS 194
9.4.1 INCREASING PREVALENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET GROWTH 194
TABLE 159 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR NASAL AND OROPHARYNGEAL SWABS, BY REGION, 2020–2027 (USD MILLION) 194
9.5 OTHER SAMPLES 195
TABLE 160 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2020–2027 (USD MILLION) 195
10 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER 196
10.1 INTRODUCTION 197
TABLE 161 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 197
10.2 CLINICAL LABORATORIES 198
10.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES TO DRIVE MARKET 198
TABLE 162 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 198
10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES 198
10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE—MAJOR FACTORS DRIVING MARKET GROWTH 198
TABLE 163 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION) 199
10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS 199
10.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET 199
TABLE 164 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION) 200
10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 200
10.5.1 HOSPITALS LARGEST END USERS OF POC DIAGNOSTICS 200
TABLE 165 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2020–2027 (USD MILLION) 201
10.6 HOME CARE AND SELF-TESTING 201
10.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE TO DRIVE MARKET 201
TABLE 166 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR HOME CARE AND SELF-TESTING, BY REGION, 2020–2027 (USD MILLION) 202
10.7 OTHER END USERS 202
TABLE 167 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 202
11 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY REGION 203
11.1 INTRODUCTION 204
TABLE 168 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 204
11.2 NORTH AMERICA 205
FIGURE 32 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SNAPSHOT 205
TABLE 169 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 170 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 171 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 172 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 173 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 174 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 175 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 176 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 209
TABLE 177 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 209
TABLE 178 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 210
TABLE 179 NORTH AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 210
11.2.1 US 211
11.2.1.1 US dominates North American POC diagnostics market 211
TABLE 180 US: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 212
TABLE 181 US: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 182 US: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 183 US: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 184 US: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214
11.2.2 CANADA 214
11.2.2.1 Rising government initiatives to support growth of POC diagnostics market in Canada 214
TABLE 185 CANADA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 215
TABLE 186 CANADA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 187 CANADA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 188 CANADA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 189 CANADA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217
11.3 EUROPE 218
TABLE 190 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 218
TABLE 191 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 219
TABLE 192 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 193 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 194 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 195 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 196 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 197 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 222
TABLE 198 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 222
TABLE 199 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 223
TABLE 200 EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 223
11.3.1 GERMANY 224
11.3.1.1 Largest market for POC diagnostics in Europe 224
TABLE 201 GERMANY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 225
TABLE 202 GERMANY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 203 GERMANY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 204 GERMANY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 205 GERMANY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 227
11.3.2 FRANCE 227
11.3.2.1 Growing public-private collaborations for product development to drive market 227
TABLE 206 FRANCE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 228
TABLE 207 FRANCE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 208 FRANCE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 209 FRANCE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 210 FRANCE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230
11.3.3 UK 230
11.3.3.1 Benefits of POC diagnostics to support market growth 230
TABLE 211 UK: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232
TABLE 212 UK: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 213 UK: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 214 UK: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 215 UK: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 234
11.3.4 ITALY 234
11.3.4.1 Rising prevalence of chronic diseases to drive demand for POC diagnostics 234
TABLE 216 ITALY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 235
TABLE 217 ITALY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 218 ITALY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 219 ITALY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 237
TABLE 220 ITALY: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 237
11.3.5 SPAIN 237
11.3.5.1 Rising geriatric population to support market growth 237
TABLE 221 SPAIN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 238
TABLE 222 SPAIN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 223 SPAIN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 224 SPAIN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 225 SPAIN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 240
11.3.6 REST OF EUROPE 240
TABLE 226 REST OF EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 241
TABLE 227 REST OF EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 228 REST OF EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 229 REST OF EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 230 REST OF EUROPE: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 243
11.4 ASIA PACIFIC 243
FIGURE 33 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SNAPSHOT 244
TABLE 231 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 245
TABLE 232 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 246
TABLE 233 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 234 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 235 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 236 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 237 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 238 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 248
TABLE 239 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 249
TABLE 240 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 249
TABLE 241 ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 250
11.4.1 JAPAN 250
11.4.1.1 Japan to dominate Asia Pacific POC diagnostics market during forecast period 250
TABLE 242 JAPAN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 251
TABLE 243 JAPAN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 244 JAPAN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 245 JAPAN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 246 JAPAN: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 253
11.4.2 CHINA 253
11.4.2.1 Rising investments by market players and government to drive market 253
TABLE 247 CHINA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 254
TABLE 248 CHINA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 249 CHINA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 250 CHINA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 256
TABLE 251 CHINA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 256
11.4.3 INDIA 256
11.4.3.1 High burden of chronic diseases to support market growth 256
TABLE 252 INDIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 258
TABLE 253 INDIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 254 INDIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 255 INDIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 256 INDIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 260
11.4.4 AUSTRALIA 260
11.4.4.1 Government initiatives to support adoption of point-of-care testing 260
TABLE 257 AUSTRALIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 261
TABLE 258 AUSTRALIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 261
TABLE 259 AUSTRALIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 260 AUSTRALIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 261 AUSTRALIA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 263
11.4.5 SOUTH KOREA 263
11.4.5.1 Increased funding and product development to propel market growth 263
TABLE 262 SOUTH KOREA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 264
TABLE 263 SOUTH KOREA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 264 SOUTH KOREA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 265 SOUTH KOREA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 266 SOUTH KOREA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 266
11.4.6 REST OF ASIA PACIFIC 266
TABLE 267 REST OF ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 267
TABLE 268 REST OF ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 269 REST OF ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 270 REST OF ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 271 REST OF ASIA PACIFIC: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 269
11.5 LATIN AMERICA 269
TABLE 272 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 269
TABLE 273 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 270
TABLE 274 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 275 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 276 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 277 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 278 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 279 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 272
TABLE 280 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 273
TABLE 281 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 273
TABLE 282 LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 274
11.5.1 BRAZIL 274
11.5.1.1 Rising prevalence of diabetes to support market growth 274
TABLE 283 BRAZIL: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 275
TABLE 284 BRAZIL: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 285 BRAZIL: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 286 BRAZIL: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 287 BRAZIL: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 277
11.5.2 MEXICO 277
11.5.2.1 Rising prevalence of diabetes and cancer to drive market 277
TABLE 288 MEXICO: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 278
TABLE 289 MEXICO: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 290 MEXICO: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 279
TABLE 291 MEXICO: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 279
TABLE 292 MEXICO: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 280
11.5.3 REST OF LATIN AMERICA 280
TABLE 293 REST OF LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 281
TABLE 294 REST OF LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 295 REST OF LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 282
TABLE 296 REST OF LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 282
TABLE 297 REST OF LATIN AMERICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 283
11.6 MIDDLE EAST & AFRICA 283
11.6.1 RISING PREVALENCE OF HIV TO DRIVE MARKET 283
TABLE 298 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 284
TABLE 299 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 300 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 301 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 302 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 303 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET FOR PREGNANCY AND FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 304 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 286
TABLE 305 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 287
TABLE 306 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 287
TABLE 307 MIDDLE EAST & AFRICA: POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET, BY SAMPLE, 2020–2027 (USD MILLION) 288
12 COMPETITIVE LANDSCAPE 289
12.1 INTRODUCTION 289
TABLE 308 OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019−2022) 290
12.2 REVENUE SHARE ANALYSIS 291
FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET 291
12.3 MARKET SHARE ANALYSIS 292
FIGURE 35 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021 292
12.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021) 293
12.4.1 STARS 293
12.4.2 EMERGING LEADERS 293
12.4.3 PERVASIVE PLAYERS 294
12.4.4 PARTICIPANTS 294
FIGURE 36 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 294
12.5 COMPETITIVE LEADERSHIP MAPPING: STARTUP/SME EVALUATION QUADRANT (2021) 295
12.5.1 PROGRESSIVE COMPANIES 295
12.5.2 RESPONSIVE COMPANIES 295
12.5.3 DYNAMIC COMPANIES 295
12.5.4 STARTING BLOCKS 295
FIGURE 37 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS) (2021) 296
12.6 COMPETITIVE BENCHMARKING 297
12.6.1 FOOTPRINT ANALYSIS OF COMPANIES 297
TABLE 309 OVERALL FOOTPRINT OF COMPANIES 297
TABLE 310 PRODUCT FOOTPRINT OF COMPANIES 298
TABLE 311 REGIONAL FOOTPRINT OF COMPANIES 299
12.7 COMPETITIVE SCENARIO 301
12.7.1 PRODUCT LAUNCHES AND APPROVALS 301
TABLE 312 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: KEY PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–OCTOBER 2022) 301
12.7.2 DEALS 302
TABLE 313 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: KEY DEALS (JANUARY 2019–OCTOBER 2022) 302
12.7.3 OTHER DEVELOPMENTS 303
TABLE 314 POINT-OF-CARE AND RAPID DIAGNOSTICS MARKET: OTHER KEY DEVELOPMENTS (JANUARY 2019–OCTOBER 2022) 303
13 COMPANY PROFILES 304
13.1 KEY PLAYERS 304
(Business Overview, Products Offered, Recent Developments, and MnM View)*
13.1.1 ABBOTT LABORATORIES 304
TABLE 315 ABBOTT LABORATORIES: BUSINESS OVERVIEW 304
FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 305
13.1.2 SIEMENS HEALTHINEERS AG 309
TABLE 316 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 309
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 310
13.1.3 F. HOFFMANN-LA ROCHE LTD. 314
TABLE 317 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 314
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 315
13.1.4 QUIDEL CORPORATION 319
TABLE 318 QUIDEL CORPORATION: BUSINESS OVERVIEW 319
FIGURE 41 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 320
13.1.5 DANAHER CORPORATION 325
TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW 325
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 326
13.1.6 BECTON, DICKINSON AND COMPANY 329
TABLE 320 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 329
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 330
13.1.7 THERMO FISHER SCIENTIFIC 333
TABLE 321 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 333
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 334
13.1.8 BIOMÉRIEUX S.A. 339
TABLE 322 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW 339
FIGURE 45 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2021) 340
13.1.9 CHEMBIO DIAGNOSTICS, INC. 346
TABLE 323 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW 346
FIGURE 46 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2021) 347
13.1.10 EKF DIAGNOSTICS 350
TABLE 324 EKF DIAGNOSTICS: BUSINESS OVERVIEW 350
FIGURE 47 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2021) 351
13.1.11 TRINITY BIOTECH PLC 353
TABLE 325 TRINITY BIOTECH PLC: BUSINESS OVERVIEW 353
FIGURE 48 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2021) 354
13.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 356
TABLE 326 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW 356
13.1.13 NOVA BIOMEDICAL 359
TABLE 327 NOVA BIOMEDICAL: BUSINESS OVERVIEW 359
13.1.14 PTS DIAGNOSTICS 362
TABLE 328 PTS DIAGNOSTICS: BUSINESS OVERVIEW 362
13.1.15 SEKISUI DIAGNOSTICS 364
TABLE 329 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW 364
13.1.16 EUROLYSER DIAGNOSTICA GMBH 366
TABLE 330 EUROLYSER DIAGNOSTICA GMBH: BUSINESS OVERVIEW 366
13.1.17 RESPONSE BIOMEDICAL 368
TABLE 331 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 368
13.1.18 ALFA SCIENTIFIC DESIGNS, INC. 370
TABLE 332 ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW 370
13.1.19 BODITECH MED INC. 371
TABLE 333 BODITECH MED INC.: BUSINESS OVERVIEW 371
13.1.20 BTNX INC. 373
TABLE 334 BTNX INC.: BUSINESS OVERVIEW 373
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 374
13.2.1 LIFESCAN IP HOLDINGS, LLC 374
13.2.2 ASCENSIA DIABETES CARE 375
13.2.3 FLUXERGY 376
13.2.4 PRECISION BIOSENSOR, INC. 377
13.2.5 ACON LABORATORIES, INC. 378
13.2.6 A. MENARINI DIAGNOSTICS S.R.L. 379
13.2.7 ORASURE TECHNOLOGIES, INC. 381
13.2.8 MANKIND PHARMA 382
13.2.9 TERUMO CORPORATION 382
13.2.10 GRIFOLS, S.A. 383
13.2.11 DIASORIN S.P.A. 384
13.2.12 ACCUBIOTECH CO., LTD. 385
13.2.13 MERIDIAN BIOSCIENCE 387
13.2.14 BIOCARTIS 388
13.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC. 389
14 APPENDIX 390
14.1 DISCUSSION GUIDE 390
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 395
14.3 CUSTOMIZATION OPTIONS 397
14.4 RELATED REPORTS 397
14.5 AUTHOR DETAILS 398